Skip to main content
Erschienen in: Inflammation 4/2014

01.08.2014

Assessment of Inflammatory Biomarkers and Oxidative Stress in Pulmonary Thromboembolism: Follow-up Results

verfasst von: Bilal Halici, Sevinc Sarinc Ulasli, Ersin Günay, Serkan Nural, Serkan Sen, Olcay Akar, Sefa Celik, Mehmet Unlu

Erschienen in: Inflammation | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Instability in circulation, hypoperfusion, hypoxia, and ischemia in pulmonary thromboembolism (PTE) may occur as a result of failure in pulmonary circulation. All these conditions cause inflammation and oxidative stress. We aimed to investigate inflammatory markers, asymmetric dimethylarginine (ADMA) levels, and the oxidant-antioxidant balance in patients with PTE. This study was conducted as a prospective case-control study. Thirty-eight patients with PTE enrolled to the study. Age- and gender-matched 38 healthy subjects without risk factors for pulmonary embolism were selected as control group. Venous blood samples were obtained from the PTE patients during the initial diagnosis and at the first month of treatment and from the control subjects. Interleukine-6 (IL-6), tumor necrosis factor alpha (TNF-α), total antioxidant status (TAS), total oxidant status (TOS), and ADMA levels were measured for all the samples. The results of patients and healthy subjects were compared. The mean age of the control group was 51.81 ± 15.18 years, and the mean age of the patients was 52.90 ± 18.22 years (p = 0.770). Deep venous thrombosis was present in 68 % of the patients. While we found significant differences between the patient and control groups in terms of IL-6, TAS, TNF-α, ADMA and oxidative stress index (OSI) values (p = 0.001, p = 0.011, p = 0.038, p = 0.028, and p = 0.024, respectively), the TOS value was not different between the groups (p = 0.080). The ADMA, TNF-α, TAS, TOS, and OSI values of the patients during the initial diagnosis and at the first month of treatment were not different (p > 0.05). The results of this study indicate an increased inflammation, endothelial damage, and oxidative stress in PTE. No difference at the first month of therapy suggests ongoing processes. We consider that these markers may be useful in the diagnosis and follow up of PTE.
Literatur
1.
Zurück zum Zitat Wicki, J., A. Perrier, T.V. Perneger, H. Bounameaux, and A.F. Junod. 2000. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 84: 548–552.PubMed Wicki, J., A. Perrier, T.V. Perneger, H. Bounameaux, and A.F. Junod. 2000. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 84: 548–552.PubMed
2.
Zurück zum Zitat Günay, E., S. Sarinc Ulasli, E. Kacar, B. Halici, E. Unlu, K. Tünay, et al. 2014. Can platelet indices predict obstruction level of pulmonary vascular bed in patients with acute pulmonary embolism? Clin Respir J 8(1): 33–40. doi:10.1111/crj.12031.PubMedCrossRef Günay, E., S. Sarinc Ulasli, E. Kacar, B. Halici, E. Unlu, K. Tünay, et al. 2014. Can platelet indices predict obstruction level of pulmonary vascular bed in patients with acute pulmonary embolism? Clin Respir J 8(1): 33–40. doi:10.​1111/​crj.​12031.PubMedCrossRef
3.
Zurück zum Zitat Girard, P., D. Musset, F. Parent, S. Maitre, C. Phlippoteau, and G. Simonneau. 1999. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest 116: 903–908.PubMedCrossRef Girard, P., D. Musset, F. Parent, S. Maitre, C. Phlippoteau, and G. Simonneau. 1999. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest 116: 903–908.PubMedCrossRef
4.
Zurück zum Zitat Muhl, D., R. Furedi, J. Cristofari, S. Ghosh, L. Bogár, B. Borsiczki, et al. 2006. Evaluation of oxidative stress in the thrombolysis of pulmonary embolism. J Thromb Thrombolysis 22: 221–228.PubMedCrossRef Muhl, D., R. Furedi, J. Cristofari, S. Ghosh, L. Bogár, B. Borsiczki, et al. 2006. Evaluation of oxidative stress in the thrombolysis of pulmonary embolism. J Thromb Thrombolysis 22: 221–228.PubMedCrossRef
5.
Zurück zum Zitat Sies, H. 1997. Oxidative stress: oxidants and antioxidants. Exp Physiol 82: 291–295.PubMed Sies, H. 1997. Oxidative stress: oxidants and antioxidants. Exp Physiol 82: 291–295.PubMed
6.
Zurück zum Zitat Valdez, L.B., S.L. Arnaiz, J. Bustamante, S. Alvarez, L.E. Costa, and A. Boveris. 2000. Free radical chemistry in biological systems. Biol Res 33: 65–70.PubMedCrossRef Valdez, L.B., S.L. Arnaiz, J. Bustamante, S. Alvarez, L.E. Costa, and A. Boveris. 2000. Free radical chemistry in biological systems. Biol Res 33: 65–70.PubMedCrossRef
7.
Zurück zum Zitat Nijveldt, R.J., T. Teerlink, C. van Guldener, H.A. Prins, A.A. van Lambalgen, C.D. Stehouwer, J.A., et al. 2003. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transplant 18: 2542–2550. Nijveldt, R.J., T. Teerlink, C. van Guldener, H.A. Prins, A.A. van Lambalgen, C.D. Stehouwer, J.A., et al. 2003. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transplant 18: 2542–2550.
8.
Zurück zum Zitat Vallance, P., and J. Leiper. 2004. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24: 1023–1030.PubMedCrossRef Vallance, P., and J. Leiper. 2004. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24: 1023–1030.PubMedCrossRef
9.
Zurück zum Zitat Nural, S., E. Günay, B. Halici, S. Celik, and M. Ünlü. 2013. Inflammatory processes and effects of continuous positive airway pressure (CPAP) in overlap syndrome. Inflammation 36: 66–74.PubMedCrossRef Nural, S., E. Günay, B. Halici, S. Celik, and M. Ünlü. 2013. Inflammatory processes and effects of continuous positive airway pressure (CPAP) in overlap syndrome. Inflammation 36: 66–74.PubMedCrossRef
10.
Zurück zum Zitat Buğdaycı, G., and E. Serin. 2005. Asimetrik Dimetilarginin (ADMA). Düzce Tip Fakultesi Dergisi 2: 36–41. Buğdaycı, G., and E. Serin. 2005. Asimetrik Dimetilarginin (ADMA). Düzce Tip Fakultesi Dergisi 2: 36–41.
11.
Zurück zum Zitat Erel, O. 2005. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38: 1103–1111.PubMedCrossRef Erel, O. 2005. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38: 1103–1111.PubMedCrossRef
12.
Zurück zum Zitat Erel, O. 2004. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37: 277–285.PubMedCrossRef Erel, O. 2004. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37: 277–285.PubMedCrossRef
13.
Zurück zum Zitat Ovechkin, A.V., D. Lominadze, K.C. Sedoris, T.W. Robinson, S.C. Tyagi, and A.M. Roberts. 2007. Lung ischemia-reperfusion injury: implications of oxidative stress and platelet-arteriolar wall interactions. Arch Physiol Biochem 113: 1–12.PubMedCentralPubMedCrossRef Ovechkin, A.V., D. Lominadze, K.C. Sedoris, T.W. Robinson, S.C. Tyagi, and A.M. Roberts. 2007. Lung ischemia-reperfusion injury: implications of oxidative stress and platelet-arteriolar wall interactions. Arch Physiol Biochem 113: 1–12.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Re, G., C. Lanzarini, I. Vaona, M. Pazzaglia, G. Palareti, L. Bassein, and C. Guarnieri. 1998. Systemically circulating oxidative species in human deep venous thrombosis. Eur J Emerg Med 5: 9–12.PubMed Re, G., C. Lanzarini, I. Vaona, M. Pazzaglia, G. Palareti, L. Bassein, and C. Guarnieri. 1998. Systemically circulating oxidative species in human deep venous thrombosis. Eur J Emerg Med 5: 9–12.PubMed
15.
Zurück zum Zitat Dias-Junior, C.A., E.M. Neto-Neves, M.F. Montenegro, and J.E. Tanus-Santos. 2010. Hemodynamic effects of inducible nitric oxide synthase inhibition combined with sildenafil during acute pulmonary embolism. Nitric Oxide 23: 284–288.PubMedCrossRef Dias-Junior, C.A., E.M. Neto-Neves, M.F. Montenegro, and J.E. Tanus-Santos. 2010. Hemodynamic effects of inducible nitric oxide synthase inhibition combined with sildenafil during acute pulmonary embolism. Nitric Oxide 23: 284–288.PubMedCrossRef
16.
Zurück zum Zitat Sousa-Santos, O., E.M. Neto-Neves, K.C. Ferraz, C.S. Ceron, E. Rizzi, R.F. Gerlach, et al. 2012. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. Naunyn Schmiedebergs Arch Pharmacol 385: 685–696.PubMedCrossRef Sousa-Santos, O., E.M. Neto-Neves, K.C. Ferraz, C.S. Ceron, E. Rizzi, R.F. Gerlach, et al. 2012. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. Naunyn Schmiedebergs Arch Pharmacol 385: 685–696.PubMedCrossRef
17.
Zurück zum Zitat Fox, E.A., and S.R. Kahn. 2005. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 94: 362–365.PubMed Fox, E.A., and S.R. Kahn. 2005. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 94: 362–365.PubMed
18.
Zurück zum Zitat Marchena Yglesias, P.J., J.A. Nieto Rodríguez, S. Serrano Martínez, O. Belinchón Moya, A. Cortés Carmona, A. Díaz de Tuesta, et al. 2006. Acute-phase reactants and markers of inflammation in venous thromboembolic disease: correlation with clinical and evolution parameters. An Med Interna 23: 105–110.PubMed Marchena Yglesias, P.J., J.A. Nieto Rodríguez, S. Serrano Martínez, O. Belinchón Moya, A. Cortés Carmona, A. Díaz de Tuesta, et al. 2006. Acute-phase reactants and markers of inflammation in venous thromboembolic disease: correlation with clinical and evolution parameters. An Med Interna 23: 105–110.PubMed
19.
Zurück zum Zitat Jezovnik, M.K., and P. Poredos. 2010. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction. Int Angiol 29: 226–231.PubMed Jezovnik, M.K., and P. Poredos. 2010. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction. Int Angiol 29: 226–231.PubMed
20.
Zurück zum Zitat Altuntaş, M., F. Atalay, M. Can, R. Altın, and M. Tor. 2011. Serum asymmetric dimethylarginine, nitrate, vitamin B(12), and homocysteine levels in individuals with pulmonary embolism. Mediat Inflamm 2011: 215057. Altuntaş, M., F. Atalay, M. Can, R. Altın, and M. Tor. 2011. Serum asymmetric dimethylarginine, nitrate, vitamin B(12), and homocysteine levels in individuals with pulmonary embolism. Mediat Inflamm 2011: 215057.
21.
Zurück zum Zitat Bakr, A., O. Pak, A. Taye, F. Hamada, R. Hemeida, W. Janssen, et al. 2013. Effects of dimethylarginine dimethylaminohydrolase-1 overexpression on the response of the pulmonary vasculature to hypoxia. Am J Respir Cell Mol Biol 49: 491–500.PubMedCrossRef Bakr, A., O. Pak, A. Taye, F. Hamada, R. Hemeida, W. Janssen, et al. 2013. Effects of dimethylarginine dimethylaminohydrolase-1 overexpression on the response of the pulmonary vasculature to hypoxia. Am J Respir Cell Mol Biol 49: 491–500.PubMedCrossRef
22.
Zurück zum Zitat Millatt, L.J., G.S. Whitley, D. Li, J.M. Leiper, H.M. Siragy, R.M. Carey, et al. 2003. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108: 1493–1498.PubMedCrossRef Millatt, L.J., G.S. Whitley, D. Li, J.M. Leiper, H.M. Siragy, R.M. Carey, et al. 2003. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108: 1493–1498.PubMedCrossRef
23.
Zurück zum Zitat Pei, Y., P. Ma, X. Wang, W. Zhang, F. Zheng, et al. 2011. Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur J Pharmacol 666: 165–172.PubMedCrossRef Pei, Y., P. Ma, X. Wang, W. Zhang, F. Zheng, et al. 2011. Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur J Pharmacol 666: 165–172.PubMedCrossRef
24.
Zurück zum Zitat Pullamsetti, S.S., R. Savai, M.B. Schaefer, J. Wilhelm, H.A. Ghofrani, N. Weissmann, et al. 2011. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. Circulation 123: 1194–1204.PubMedCrossRef Pullamsetti, S.S., R. Savai, M.B. Schaefer, J. Wilhelm, H.A. Ghofrani, N. Weissmann, et al. 2011. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. Circulation 123: 1194–1204.PubMedCrossRef
Metadaten
Titel
Assessment of Inflammatory Biomarkers and Oxidative Stress in Pulmonary Thromboembolism: Follow-up Results
verfasst von
Bilal Halici
Sevinc Sarinc Ulasli
Ersin Günay
Serkan Nural
Serkan Sen
Olcay Akar
Sefa Celik
Mehmet Unlu
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2014
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-9844-y

Weitere Artikel der Ausgabe 4/2014

Inflammation 4/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.